The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2021 | Prognostic factors in mycosis fungoides
Evangelina Papadavid, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the impacts of the COVID-19 pandemic on the management and treatment of patients with cutaneous T-cell lymphoma (CTCL), in particular highlighting the impacts of postponing treatments. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
